

August 5, 2015

Dear Manufacturers,

I am writing on behalf of Memorial Health Center, now known as Aspirus Medford Hospital & Clinics, Inc. (AMH) (340B ID #CAH 521324-00) to inform manufacturers that AMH recently underwent an audit by the Health Resources and Services Administration (HRSA) of AMH's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, AMH qualified for the 340B Program as a critical access hospital in Medford, Wisconsin and has participated in the 340B Program since January 1, 2011.

Through the audit process, AMH was found to have non-compliance within their 340B Program and responsible for repayment as result of the following finding: "Memorial Health Center (AMH) dispensed 340B drugs to ineligible individuals, as prohibited by 42 U.S.C. 256b(a)(5)(B)."

AMH has identified the affected manufacturers and will contact each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers. If manufacturers do not receive notification from AMH and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter, please contact Greg Shaw, Chief Financial Officer, 715-748-8159, Aspirus Medford Hospital & Clinics, Inc., 135 South Gibson Street, Medford, Wisconsin 54451.

Sincerely,

Greg Shaw
Chief Financial Officer
Aspirus Medford Hospital & Clinics, Inc.
135 South Gibson Street
Medford, Wisconsin 54451